Within the centralized and point-of-care solutions business, integrated serum work area solutions drove growth with immunodiagnostics sales rising 13 percent.
In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year.
The agency cleared the company's C-reactive protein, which is based on its Multi-Array technology used by life science researchers for 20 years.
Sebia and Janssen Biotech collaborated on the development of the test, which is for assessing patients treated with Darzalex.
The firm saw double-digit growth in both its core diagnostics and life sciences businesses, with losses in its Magellan lead testing division.
The device consists of a reservoir that enables the analyte to contact only the top of a screen-printed electrode, increasing sensitivity.
A test being developed by researchers at Stanford University and Enable Biosciences could be used for HIV screening sooner than traditional immunoassays.
The tests detect Campylobacter jejuni and Campylobacter coli and improve upon currently available immunoassays and culture tests, the firm said.
The companies plan to market an HIV rapid test using a single drop of blood that leverages Atomo's lateral-flow platform and Access Bio's rapid test.
Diazyme's managing director said that the assay enables clinical labs "of almost any size" to run a vitamin D test in house without specialized instruments.
The new deal expands an earlier agreement and allows Immunodiagnostic to sell assays developed by Technogenetics under the IDS brand.
The multi-analyte assay could screen for cancers that currently lack early-stage detection methods, including ovarian, liver, stomach, pancreatic, and esophageal cancers.
BCBS of Illinois is the largest PPO network in the state, covering roughly 7.9 million people.
The three firms each had 510(k) clearances for multiple products from the FDA last month for marketing.
The company recorded €13.8 billion in revenues in fiscal 2017, including €4.2 billion in diagnostics, €8.2 billion in imaging, and €1.5 billion in advanced therapies.
The Ventana MMR IHC Panel is for detecting certain proteins associated with mismatch repair, and for differentiating between sporadic colorectal cancer and probable Lynch syndrome.
Luminex was bullish about its molecular diagnostics business, Natera outlined its work with pharmaceutical firms, and Oxford discussed its plans in TB and tick-borne diseases.
The funding will support further development of an existing serum-based assay and expansion of the test to use saliva samples.
The companies are working together to pair Qiagen's QuantiFeron-TB diagnostic test with DiaSorin's Liaison family of automated analyzers.
The firm plans to use $110 million of the net cash proceeds to pay down debt.